Latest Insider Transactions at Pandion Therapeutics, Inc. (PAND)
This section provides a real-time view of insider transactions for Pandion Therapeutics, Inc. (PAND). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pandion Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pandion Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Eric D Larson Vice President, Finance |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,125
-100.0%
|
$1,327,500
$60.0 P/Share
|
|
Apr 01
2021
|
Jill Carroll Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,674,221
-100.0%
|
$340,453,260
$60.0 P/Share
|
|
Apr 01
2021
|
Donald Frail Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
61,113
-100.0%
|
$3,666,780
$60.0 P/Share
|
|
Apr 01
2021
|
Nancy Stagliano Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
73,067
-100.0%
|
$4,384,020
$60.0 P/Share
|
|
Apr 01
2021
|
Nancy Stagliano Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,000
-100.0%
|
$60,000
$60.0 P/Share
|
|
Apr 01
2021
|
John Sundy Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
115,826
-100.0%
|
$6,949,560
$60.0 P/Share
|
|
Apr 01
2021
|
Daniel J. Becker Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,827,883
-100.0%
|
$169,672,980
$60.0 P/Share
|
|
Apr 01
2021
|
Daniel J. Becker Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,000
-100.0%
|
$60,000
$60.0 P/Share
|
|
Apr 01
2021
|
Christopher Fuglesang Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,131,135
-100.0%
|
$127,868,100
$60.0 P/Share
|
|
Apr 01
2021
|
Rahul Kakkar Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
702,515
-100.0%
|
$42,150,900
$60.0 P/Share
|
|
Apr 01
2021
|
Rahul Kakkar Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,000
-100.0%
|
$840,000
$60.0 P/Share
|
|
Apr 01
2021
|
Gregg Beloff Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,196
-100.0%
|
$791,760
$60.0 P/Share
|
|
Apr 01
2021
|
Edward D. Freedman Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
54,460
-100.0%
|
$3,267,600
$60.0 P/Share
|
|
Apr 01
2021
|
Alan L Crane Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,537,736
-100.0%
|
$212,264,160
$60.0 P/Share
|
|
Apr 01
2021
|
Alan L Crane Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
84,158
-100.0%
|
$5,049,480
$60.0 P/Share
|
|
Apr 01
2021
|
Vikas Goyal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
87,764
-100.0%
|
$5,265,840
$60.0 P/Share
|
|
Apr 01
2021
|
Joanne L. Viney Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,200
-100.0%
|
$72,000
$60.0 P/Share
|
|
Apr 01
2021
|
Joanne L. Viney Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
503,254
-100.0%
|
$30,195,240
$60.0 P/Share
|
|
Nov 19
2020
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Indirect |
197,716
+6.53%
|
$2,965,740
$15.12 P/Share
|
|
Nov 18
2020
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Indirect |
14,197
+0.54%
|
$212,955
$15.26 P/Share
|
|
Nov 17
2020
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Indirect |
15,197
+0.29%
|
$227,955
$15.03 P/Share
|
|
Jul 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
361,111
+16.94%
|
$6,499,998
$18.0 P/Share
|
|
Jul 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,408,912
+50.0%
|
-
|
|
Jul 21
2020
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
361,111
+13.84%
|
$6,499,998
$18.0 P/Share
|
|
Jul 21
2020
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,887,193
+32.79%
|
-
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
722,222
+25.52%
|
$12,999,996
$18.0 P/Share
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
23,622
+50.0%
|
-
|
|
Jul 21
2020
|
Boxer Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,385,291
+50.0%
|
-
|